吉西他滨联合方案治疗复发或难治性非霍奇金淋巴瘤的疗效观察

Observation of gemcitabine combination therapy of relapsed or refractory non-Hodgkin′s lymphoma

目的观察吉西他滨联合奥沙利铂、地塞米松治疗复发或难治性非霍奇金淋巴瘤的近期疗效和不良反应。方法第1、8天,吉西他滨1 000mg/m2;第2天,奥沙利铂100mg/m2;第1～4天,地塞米松40mg/d,均采用静脉滴注,21～28d为1个周期,至少完成2个周期后评价疗效。结果 21例患者中,16例获得缓解(76.2%),其中完全缓解7例(33.3%),部分缓解9例(42.9%)。主要不良反应表现为Ⅰ～Ⅲ度骨髓抑制和轻、中度的消化道反应。结论吉西他滨联合奥沙利铂、地塞米松治疗复发或难治性非霍奇金淋巴瘤近期疗效较好,患者可以耐受其不良反应,安全性较高,是一个值得进一步验证的治疗方案。

Objective To evaluate the effect and toxicity of gemcitabine combined with oxaliplatin and dexamethasone in the treatment of relapsed or refractory of non-Hodgkin′s lymphoma.Methods 21 patients with histologically confirmed relapsed or refractory non-Hodgkin′s lymphoma were enrolled in this study.The chemotherapy regimen consisted of gemcitabine（1 000 mg/m2,iv.gtt,d1,8）,oxaliplatin（100 mg/m2,iv.gtt,d2） and dexamethasone（40 mg/d,iv.gtt,d1-4） was given every three to four weeks,and every patient was treated for no less than 2 cycles.Results 16 out of the 21 patients（76.2%） showed response including 7 patients with complete response and 9 patients with partial response.The main drug related toxic effects wereⅠ-Ⅲ degree bone marrow depression and mild gastrointestina1 reactions in most patients.Conclusion The combination of gemcitabine,oxaliplatin and dexamethasone possesses better short term efficacy and acceptable toxieity.This protocol is worthy to be further confirmed as salvage for relapsed or refractory non-Hodgkin′s lymphoma.